logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

U.S. Onychomycosis Market, By Treatment (Drugs, Laser, Photodynamic Therapy), By End User (Hospital, Clinics, Others) opportunities and forecast 2020-2027

  • DLR2227
  • 24 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Onychomycosis is nail infection caused by the fungus–Trichophyton rubrum. Currently, about 2-3% of the population in the U.S. are suffering from onynchomycosis. The infection is majorly of four types which include proximal subungual onychomycosis, distal subungual onychomycosis, and white superficial onychomycosis and candida infections of nail.

Globally, improved prevalence rate of the diabetic patients and increasing geriatric population, consistent raise in prevalence of infections, rise in consciousness among common people concerning the diagnosis and treatment, and development of the novel medications are prime growth drivers of the Onychomycosis market. Additionally, emerging economies Including India, China, and others, will create opportunities for the global Onychomycosis market. On the other hand, better circulation of off label products and the negligence towards the infection especially in underdeveloped economies are key restraints for the global Onychomycosis market.

Segment Overview

Photodynamic therapy by the treatment segment is expected to grow at a highest rate. The therapy is the most progressive treatment option available for the disease treatment. Expert medical professionals are essential to avoid any risk throughout the treatment period. However, according to WHO, there will be shortage of almost 12.9 million healthcare workforces by 2035 across the world. The demand for the plastic surgeons has surged in last few decades, however, the supply of plastic surgeons has deteriorated. The demand-supply gap of the plastic surgeons necessary to perform the photodynamic therapy treatment may deter growth of the market.

Regional Overview

The U.S. onychomycosis market is estimated to grow at healthy growth rate throughout the forecast period. The U.S. onychomycosis market is maintained by numerous growth drivers, such as increasing per capita healthcare spending, growing diabetic patients, elderly population, and introduction of new drugs. However, the market faces various challenges, such as low awareness, reimbursements, side effects, and various others.

Competitor overview

There is increasing trend of partnerships being observed among leading players in the market. Companies are entering into sales and marketing agreements for their product promotion. For instance, 2014, Anacor Pharmaceuticals Inc. come in an exclusive agreement with the Novartis AG for marketing and sales of their products in U.S. market. Moreover, 2013, Moberg Pharma engaged into a distribution agreement with the Leosons International LLC for marketing of Kerasal nail product in Middle East and North Africa.

Key Players
  1. Valeant PharmaceuticalsInc.,
  2. Galderma S.A.,
  3. Novartis AG, Pfizer, Inc.,
  4. Moberg Pharma AB,
  5. Johnson & Johnson Services, Inc.,
  6. Bayer AG,
  7. Dr. Reddy’s Laboratories Ltd.,
  8. Cipla Ltd.,
  9. Medimetriks Pharmaceuticals, Inc.,
  10. Lumenis Ltd.,
  11. Biofrontera AG,
  12. Leo Pharma A/S

Market Segmentation

By Treatment
  • Drugs
  • Laser
  • Photodynamic Therapy
By End User
  • Hospitals
  • Clinics
  • Others
By Geography
  • US


1 Introduction 6

  • 1.1 Onychomycosis: An Overview 6
  • 1.2 Scope of Study 6
    • 1.2.1 Research Objective 6
  • 1.3 Market Structure 7
  • 1.4 Types of Onychomycosis 7
  • 1.5 Signs and Symptoms 8
    • 1.5.1 Symptoms of Onychomycosis Nail Infection Based on Subtype 8
  • 1.6 Cause 9
  • 1.7 Treatments for Onychomycosis 10

2 Research Methodolgy 11

  • 2.1 Primary Research 12
  • 2.2 Secondary Research 12

3 Market Dynamics 13

  • 3.1 Growth Drivers 13
    • 3.1.1 Rising Per-capita Healthcare Expenditure 13
    • 3.1.2 Increasing Diabetic Patients 13
    • 3.1.3 Increasing Prevalence of Peripheral Artery Disease (PAD) 13
  • 3.2 Challenges 14
    • 3.2.1 Low awareness 14
    • 3.2.2 Side effects 14

4 US Onychomycosis 15

  • 4.1 US Onychomycosis Market 15
    • 4.1.1 US Onychomycosis Market By Prevalence 15
    • 4.1.2 US Nail Care Market 17
  • 4.2 US Jublia Drug Market 17
  • 4.3 US Kerydin Drug market 19
  • 4.4 US Generic Drugs Market 19

5 Competitive Landscape 21

  • 5.1 Market Share Analysis 21

6 Company Profile 22

  • 6.1 Novartis 22
    • 6.1.1 Overview 22
    • 6.1.2 Product/Business Segment Overview 22
    • 6.1.3 Financial Updates 23
    • 6.1.4 Key Developments 23
  • 6.2 Anacor Pharmaceuticals 24
    • 6.2.1 Overview 24
    • 6.2.2 Financial Updates 24
    • 6.2.3 Key Developments 25
  • 6.3 Johnson and Johnson 26
    • 6.3.1 Overview 26
    • 6.3.2 Product/Business Segment Overview 26
    • 6.3.3 Financial Updates 26
    • 6.3.4 Key Developments 27
  • 6.4 Valeant Pharmaceuticals 28
    • 6.4.1 Overview 28
    • 6.4.2 Product/Business Segment Overview 28
    • 6.4.3 Financial Updates 29
    • 6.4.4 Key Developments 29

Report You Might be Interested